Tff Historical Balance Sheet

TFFP Stock

USD 0.34 0.03 9.68%

Trend analysis of Tff Pharmaceuticals balance sheet accounts such as Total Liabilities of 1.3 M, Total Assets of 11.4 M, Cash of 5.2 M or Non Current Assets Total of 4.7 M provides information on Tff Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Tff Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Tff Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Tff Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Tff Pharmaceuticals is a good buy for the upcoming year.

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tff Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census.

To learn how to invest in Tff Stock, please use our How to Invest in Tff Pharmaceuticals guide.

About Tff Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Tff Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Tff Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Tff Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Tff currently owns. An asset can also be divided into two categories, current and non-current.

Tff Pharmaceuticals Balance Sheet Chart

At this time, Tff Pharmaceuticals' Property Plant And Equipment Net is relatively stable compared to the past year. As of 12/01/2024, Property Plant And Equipment Gross is likely to grow to about 2.3 M, while Accounts Payable is likely to drop slightly above 759.2 K.

Total Current Liabilities Accounts Payable Total Liab Common Stock Shares Outstanding Property Plant Equipment

Add Fundamental

Total Current Liabilities

Total Current Liabilities is an item on Tff Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Tff Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accounts Payable

An accounting item on the balance sheet that represents Tff Pharmaceuticals obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Tff Pharmaceuticals are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Most accounts from Tff Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Tff Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tff Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census.

To learn how to invest in Tff Stock, please use our How to Invest in Tff Pharmaceuticals guide.At this time, Tff Pharmaceuticals' Property Plant And Equipment Net is relatively stable compared to the past year. As of 12/01/2024, Property Plant And Equipment Gross is likely to grow to about 2.3 M, while Accounts Payable is likely to drop slightly above 759.2 K.

	2021	2022	2023	2024 (projected)
Total Liabilities	2.0M	1.2M	2.5M	1.3M
Accounts Payable	1.5M	919.6K	958.4K	759.2K

Total Liab Accounts Payable

Tff Pharmaceuticals balance sheet Correlations

	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Total Liab	Common Stock Shares Outstanding	Non Current Liabilities Total	Net Invested Capital	Net Working Capital	Other Current Liab	Net Debt	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Deferred Long Term Liab	Capital Stock	Common Stock	Other Liab	Property Plant And Equipment Net	Current Deferred Revenue	Retained Earnings Total Equity	Property Plant And Equipment Gross
Total Current Liabilities		0.56	0.87	-0.9	0.84	0.88	-0.78	0.22	0.51	0.47	0.37	-0.18	-0.71	0.18	0.83	0.83	0.7	0.86	-0.71	-0.8	0.28	-0.71	0.65	0.69	-0.81	0.65
Total Stockholder Equity	0.56		0.74	-0.45	0.88	0.74	-0.84	0.79	0.98	0.99	-0.51	-0.9	0.03	0.9	0.79	0.74	0.85	0.66	0.03	-0.82	0.83	0.03	0.36	0.28	-0.47	0.36
Net Tangible Assets	0.87	0.74		-0.91	0.88	0.87	-0.97	0.4	0.77	0.65	0.06	-0.42	-0.58	0.42	0.97	0.94	0.86	0.95	-0.58	-0.98	0.57	-0.58	0.73	0.74	-0.81	0.73
Retained Earnings	-0.9	-0.45	-0.91		-0.75	-0.79	0.8	-0.02	-0.47	-0.33	-0.32	0.05	0.72	-0.05	-0.87	-0.89	-0.65	-0.95	0.72	0.83	-0.37	0.72	-0.88	-0.92	0.92	-0.88
Accounts Payable	0.84	0.88	0.88	-0.75		0.87	-0.87	0.52	0.86	0.82	-0.13	-0.64	-0.29	0.64	0.91	0.91	0.91	0.87	-0.29	-0.88	0.68	-0.29	0.58	0.56	-0.73	0.58
Total Liab	0.88	0.74	0.87	-0.79	0.87		-0.88	0.48	0.69	0.68	0.07	-0.42	-0.43	0.42	0.91	0.89	0.7	0.86	-0.43	-0.88	0.47	-0.43	0.56	0.61	-0.7	0.56
Common Stock Shares Outstanding	-0.78	-0.84	-0.97	0.8	-0.87	-0.88		-0.57	-0.86	-0.78	0.13	0.58	0.42	-0.57	-0.97	-0.91	-0.86	-0.89	0.42	1.0	-0.68	0.42	-0.65	-0.64	0.71	-0.65
Non Current Liabilities Total	0.22	0.79	0.4	-0.02	0.52	0.48	-0.57		0.74	0.84	-0.55	-0.84	0.18	0.83	0.43	0.31	0.64	0.21	0.18	-0.54	0.53	0.18	-0.15	-0.17	0.11	-0.15
Net Invested Capital	0.51	0.98	0.77	-0.47	0.86	0.69	-0.86	0.74		0.96	-0.5	-0.9	0.01	0.9	0.81	0.76	0.87	0.68	0.01	-0.85	0.84	0.01	0.38	0.3	-0.49	0.38
Net Working Capital	0.47	0.99	0.65	-0.33	0.82	0.68	-0.78	0.84	0.96		-0.57	-0.94	0.12	0.94	0.71	0.65	0.8	0.56	0.12	-0.76	0.81	0.12	0.24	0.16	-0.36	0.24
Other Current Liab	0.37	-0.51	0.06	-0.32	-0.13	0.07	0.13	-0.55	-0.5	-0.57		0.7	-0.77	-0.71	-0.05	-0.02	-0.22	0.07	-0.77	0.1	-0.75	-0.77	0.06	0.19	-0.2	0.06
Net Debt	-0.18	-0.9	-0.42	0.05	-0.64	-0.42	0.58	-0.84	-0.9	-0.94	0.7		-0.35	-1.0	-0.49	-0.43	-0.67	-0.31	-0.35	0.55	-0.75	-0.35	0.01	0.11	0.11	0.01
Other Assets	-0.71	0.03	-0.58	0.72	-0.29	-0.43	0.42	0.18	0.01	0.12	-0.77	-0.35		0.36	-0.41	-0.39	-0.3	-0.49	1.0	0.45	0.26	1.0	-0.46	-0.54	0.55	-0.46
Cash And Short Term Investments	0.18	0.9	0.42	-0.05	0.64	0.42	-0.57	0.83	0.9	0.94	-0.71	-1.0	0.36		0.49	0.43	0.67	0.31	0.36	-0.55	0.76	0.36	-0.01	-0.11	-0.11	-0.01
Common Stock Total Equity	0.83	0.79	0.97	-0.87	0.91	0.91	-0.97	0.43	0.81	0.71	-0.05	-0.49	-0.41	0.49		0.99	0.84	0.97	-0.41	-0.97	0.65	-0.41	0.72	0.74	-0.8	0.72
Capital Surpluse	0.83	0.74	0.94	-0.89	0.91	0.89	-0.91	0.31	0.76	0.65	-0.02	-0.43	-0.39	0.43	0.99		0.8	0.99	-0.39	-0.92	0.64	-0.39	0.77	0.79	-0.85	0.77
Other Current Assets	0.7	0.85	0.86	-0.65	0.91	0.7	-0.86	0.64	0.87	0.8	-0.22	-0.67	-0.3	0.67	0.84	0.8		0.77	-0.3	-0.86	0.67	-0.3	0.49	0.46	-0.54	0.49
Other Stockholder Equity	0.86	0.66	0.95	-0.95	0.87	0.86	-0.89	0.21	0.68	0.56	0.07	-0.31	-0.49	0.31	0.97	0.99	0.77		-0.49	-0.9	0.59	-0.49	0.84	0.87	-0.9	0.84
Deferred Long Term Liab	-0.71	0.03	-0.58	0.72	-0.29	-0.43	0.42	0.18	0.01	0.12	-0.77	-0.35	1.0	0.36	-0.41	-0.39	-0.3	-0.49		0.45	0.26	1.0	-0.46	-0.54	0.55	-0.46
Capital Stock	-0.8	-0.82	-0.98	0.83	-0.88	-0.88	1.0	-0.54	-0.85	-0.76	0.1	0.55	0.45	-0.55	-0.97	-0.92	-0.86	-0.9	0.45		-0.66	0.45	-0.66	-0.66	0.73	-0.66
Common Stock	0.28	0.83	0.57	-0.37	0.68	0.47	-0.68	0.53	0.84	0.81	-0.75	-0.75	0.26	0.76	0.65	0.64	0.67	0.59	0.26	-0.66		0.26	0.55	0.43	-0.48	0.55
Other Liab	-0.71	0.03	-0.58	0.72	-0.29	-0.43	0.42	0.18	0.01	0.12	-0.77	-0.35	1.0	0.36	-0.41	-0.39	-0.3	-0.49	1.0	0.45	0.26		-0.46	-0.54	0.55	-0.46
Property Plant And Equipment Net	0.65	0.36	0.73	-0.88	0.58	0.56	-0.65	-0.15	0.38	0.24	0.06	0.01	-0.46	-0.01	0.72	0.77	0.49	0.84	-0.46	-0.66	0.55	-0.46		0.97	-0.91	1.0
Current Deferred Revenue	0.69	0.28	0.74	-0.92	0.56	0.61	-0.64	-0.17	0.3	0.16	0.19	0.11	-0.54	-0.11	0.74	0.79	0.46	0.87	-0.54	-0.66	0.43	-0.54	0.97		-0.88	0.97
Retained Earnings Total Equity	-0.81	-0.47	-0.81	0.92	-0.73	-0.7	0.71	0.11	-0.49	-0.36	-0.2	0.11	0.55	-0.11	-0.8	-0.85	-0.54	-0.9	0.55	0.73	-0.48	0.55	-0.91	-0.88		-0.91
Property Plant And Equipment Gross	0.65	0.36	0.73	-0.88	0.58	0.56	-0.65	-0.15	0.38	0.24	0.06	0.01	-0.46	-0.01	0.72	0.77	0.49	0.84	-0.46	-0.66	0.55	-0.46	1.0	0.97	-0.91

Click cells to compare fundamentals

Tff Pharmaceuticals Account Relationship Matchups

Tff Pharmaceuticals balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Current Liabilities	410.6K	1.3M	2.0M	1.1M	2.4M	2.5M
Total Stockholder Equity	27.6M	37.3M	38.7M	22.9M	9.6M	9.1M
Net Tangible Assets	(3.2M)	27.6M	37.3M	38.7M	44.5M	46.8M
Retained Earnings	(15.7M)	(34.3M)	(65.3M)	(97.1M)	(118.3M)	(112.4M)
Accounts Payable	410.6K	1.3M	1.5M	919.6K	958.4K	759.2K
Total Liab	1.5M	1.3M	2.0M	1.2M	2.5M	1.3M
Total Assets	29.2M	38.7M	40.7M	24.1M	12.0M	11.4M
Cash	28.1M	35.3M	33.8M	16.6M	5.5M	5.2M
Common Stock Shares Outstanding	276.2K	817.0K	992.8K	1.2M	1.8M	1.7M
Non Current Liabilities Total	1.1M	1.3M	416.9K	110.1K	31.7K	30.2K
Net Invested Capital	27.6M	37.3M	38.7M	22.9M	9.6M	9.1M
Total Current Assets	29.2M	37.6M	38.8M	19.0M	7.6M	7.2M
Net Working Capital	28.8M	36.2M	36.9M	17.9M	5.2M	4.9M
Net Debt	(28.1M)	(35.3M)	(33.8M)	(16.4M)	(5.4M)	(5.6M)
Cash And Short Term Investments	28.1M	35.3M	33.8M	16.6M	5.5M	5.2M
Liabilities And Stockholders Equity	29.2M	38.7M	40.7M	24.1M	12.0M	20.7M
Other Current Assets	1.1M	4.5M	2.4M	2.2M	1.7M	2.2M
Other Stockholder Equity	43.3M	71.6M	104.1M	120.1M	128.0M	88.0M
Accumulated Other Comprehensive Income	(29.2M)	(51.5K)	(48.9K)	(139.3K)	(148.2K)	(155.6K)
Capital Stock	18.5K	22.5K	25.4K	36.2K	2.4K	2.3K
Common Stock	18.5K	22.5K	25.4K	36.2K	2.4K	2.3K

Pair Trading with Tff Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tff Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tff Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Tff Stock

0.68	JNJ	Johnson Johnson Sell-off Trend	Pair Corr
0.85	PFE	Pfizer Inc Aggressive Push	Pair Corr

Moving against Tff Stock

0.77	FNMFO	Federal National Mortgage	Pair Corr
0.73	AVAL	Grupo Aval	Pair Corr
0.68	AXP	American Express Fiscal Year End 24th of January 2025	Pair Corr
0.54	TRV	The Travelers Companies Fiscal Year End 17th of January 2025	Pair Corr
0.52	CIB	Bancolombia SA ADR	Pair Corr

The ability to find closely correlated positions to Tff Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Tff Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Tff Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Tff Pharmaceuticals to buy it.

The correlation of Tff Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Tff Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Tff Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Tff Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Tff Stock Analysis

When running Tff Pharmaceuticals' price analysis, check to measure Tff Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tff Pharmaceuticals is operating at the current time. Most of Tff Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tff Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tff Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tff Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Tff Historical Balance Sheet

About Tff Balance Sheet Analysis

Tff Pharmaceuticals Balance Sheet Chart

Total Current Liabilities

Accounts Payable

Total Liab

Common Stock Shares Outstanding

Tff Pharmaceuticals balance sheet Correlations

Tff Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Tff Pharmaceuticals balance sheet Accounts

Pair Trading with Tff Pharmaceuticals

Moving together with Tff Stock

Moving against Tff Stock

Additional Tools for Tff Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Capital Stock	+ 1.0	Common Stock Shares Outstanding
Deferred Long Term Liab	+ 1.0	Other Assets
Other Liab	+ 1.0	Other Assets
Other Liab	+ 1.0	Deferred Long Term Liab
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Net Working Capital	+ 0.99	Total Stockholder Equity

Cash And Short Term Investments	- 1.0	Net Debt
Capital Stock	- 0.98	Net Tangible Assets
Capital Stock	- 0.97	Common Stock Total Equity
Common Stock Total Equity	- 0.97	Common Stock Shares Outstanding
Common Stock Shares Outstanding	- 0.97	Net Tangible Assets
Other Stockholder Equity	- 0.95	Retained Earnings